IMV Inc. (IMV) Reports Q1 Loss of $0.10
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
IMV Inc. Announces First Quarter 2021 Financial and Operational Results and Expansion of its Clinical Pipeline
May 12, 2021 7:05 AM EDTPhase 2B study in r/r DLBCL to begin in Q2 of this year
New investigator-initiated study of maveropepimut-S in breast cancer to be initiated this summer
First in human dual-targeted immunotherapy (DPX-SurMAGE) study in bladder cancer later in the year
Two recognized senior leaders joined Board of Directors
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)-- IMV Inc. (the Company or IMV) (TSX: IMV; NASDAQ: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced its financial and... More
